Citius Oncology files draft information statement on warrant, loan conversion share issuance

• Shareholders authorized share issuance tied to a new term-loan facility of up to USD 25 million, including stock issuable if lenders convert up to USD 4 million of outstanding loan principal at USD 1.08 per share.
• The authorization also covers shares underlying lender warrants with a USD 0.90 exercise price, sized to USD 1 million of warrant value with additional warrant value linked to any funded Tranche 2 or Tranche 3 borrowings.
• Additional share issuance was authorized for warrants issued in May, including May Common Warrants for 25,555,556 shares at USD 0.90, May PA Warrants for 894,444 shares at USD 1.125.
• Holders also received authorization to exercise amended December warrants covering 15,697,024 shares, with the exercise price reset to USD 0.90 and the term extended to five years from the approval date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-059053), on May 19, 2026, and is solely responsible for the information contained therein.